Literature DB >> 8867380

A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro.

X You1, M J Arrowood, M Lejkowski, L Xie, R F Schinazi, J R Mead.   

Abstract

A chemiluminescence immunoassay (CLIA) was developed to detect Cryptosporidium parvum growth in Madin-Darby canine kidney (MDCK) cell cultures. Optimal results were obtained when MDCK cells were plated at a density of 1 x 10(4) cells/well (96-well plate) and maintained as a monolayer for 4 days prior to infection with 2 x 10(4) parasites/well. Two compounds (paromomycin and maduramicin) were evaluated and shown to have selective activity against C. parvum in a dose-dependent manner. There was excellent correlation between CLIA and immunofluorescence assay when assessing anti-C. parvum agents in MDCK cells. CLIA offers advantages over conventional enzyme-linked immunosorbent assay and immunofluorescence assay methods in that it is more sensitive and efficient. The combination of CLIA and MDCK culture provides an efficient tool for evaluating potential anti-cryptosporidial compounds prior to testing in animal models.

Entities:  

Mesh:

Year:  1996        PMID: 8867380     DOI: 10.1111/j.1574-6968.1996.tb08057.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  10 in total

Review 1.  In vitro cultivation of cryptosporidium species.

Authors:  Michael J Arrowood
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

2.  In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds.

Authors:  Klaus Teichmann; Maxime Kuliberda; Gerd Schatzmayr; Franz Hadacek; Anja Joachim
Journal:  Parasitol Res       Date:  2012-01-26       Impact factor: 2.289

3.  Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH.

Authors:  Sivapriya Kirubakaran; Suresh Kumar Gorla; Lisa Sharling; Minjia Zhang; Xiaoping Liu; Soumya S Ray; Iain S Macpherson; Boris Striepen; Lizbeth Hedstrom; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2012-01-24       Impact factor: 2.823

4.  Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro.

Authors:  Xiaomin Cai; Keith M Woods; Steve J Upton; Guan Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Low-pressure UV inactivation and DNA repair potential of Cryptosporidium parvum oocysts.

Authors:  G A Shin; K G Linden; M J Arrowood; M D Sobsey
Journal:  Appl Environ Microbiol       Date:  2001-07       Impact factor: 4.792

6.  Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis.

Authors:  J W Benbow; E L Bernberg; A Korda; J R Mead
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Comparison of in vitro cell culture and a mouse assay for measuring infectivity of Cryptosporidium parvum.

Authors:  Paul A Rochelle; Marilyn M Marshall; Jan R Mead; Anne M Johnson; Dick G Korich; Jeffrey S Rosen; Ricardo De Leon
Journal:  Appl Environ Microbiol       Date:  2002-08       Impact factor: 4.792

8.  Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis.

Authors:  Nwakaso N Umejiego; Deviprasad Gollapalli; Lisa Sharling; Anna Volftsun; Jennifer Lu; Nicole N Benjamin; Adam H Stroupe; Thomas V Riera; Boris Striepen; Lizbeth Hedstrom
Journal:  Chem Biol       Date:  2008-01

9.  Modulation of gene expression of three Cryptosporidium parvum ATP-binding cassette transporters in response to drug treatment.

Authors:  Alvaro J Benitez; Nina McNair; Jan Mead
Journal:  Parasitol Res       Date:  2007-08-21       Impact factor: 2.289

10.  A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase.

Authors:  Lisa Sharling; Xiaoping Liu; Deviprasad R Gollapalli; Sushil K Maurya; Lizbeth Hedstrom; Boris Striepen
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.